Evidence map›Paper›PMID 28051087›Full record

ArticleMucosal immunology2017

Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility.

K K Smith-McCune, J F Hilton, U Shanmugasundaram, J W Critchfield, R M Greenblatt, D Seidman, S Averbach, L C Giudice, B L Shacklett

Open access · hybridAbstract read
In one paragraph

Article in Mucosal immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Endometriosis and adenomyosis unveiled through single-cell glasses.American journal of obstetrics and gynecology · 2025
    Review
  8. Review
  9. Safety and effectiveness of seahorse extract (Journal of advanced veterinary and animal research · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

K K Smith-McCuneDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, California, USA.
J F HiltonDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
U ShanmugasundaramDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA.
J W CritchfieldDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA.
R M GreenblattDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
D SeidmanDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, California, USA.
S AverbachDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, California, USA.
L C GiudiceDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, California, USA.
B L ShacklettDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA.
University of California, San Francisco · USUniversity of California, Davis · USEmory University · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
Viral and Host Factors Promoting Male-to-Female Transmission of HIVP01AI083050 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GIUDICE, LINDA C, GREENBLATT, RUTH MARTHA · 2009 to 2013
$10.1M
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI ROAN, NADIA R · 2017 to 2021
$8.5M
Reproductive Tract Effects of the Intrauterine Device: Implications for HIV RiskR01AI111925 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SMITH-MCCUNE, KAREN K · 2014 to 2017
$2.5M
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR012088 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI CURRY, FITZ-ROY E · 1996 to 1996
–
NCATS NIH HHS KL2 TR000143NCATS NIH HHS UL1 TR000004NCI NIH HHS P30 CA082103NCI NIH HHS P30 CA093373NCRR NIH HHS C06 RR012088NCRR NIH HHS S10 RR026825NIAID NIH HHS P01 AI083050NIAID NIH HHS P01 AI131374NIAID NIH HHS R01 AI111925
6 · The paper itself

Abstract

Depot-medroxyprogesterone acetate is a commonly used injectable contraceptive that has been associated with an increased risk of HIV acquisition. This study compares effects of depot-medroxyprogesterone acetate on immune parameters from several upper reproductive tract compartments relevant to HIV-1 susceptibility in repetitive samples from 15 depot-medroxyprogesterone acetate users and 27 women not on hormonal contraceptives. Compared with samples from unexposed women in the mid-luteal phase, depot-medroxyprogesterone acetate use was associated with: increased endocervical concentrations of MCP1 and IFNalpha2; decreased endocervical concentrations of IL1beta and IL6; increased proportions of endometrial CD4+ and CD8+ cells expressing the activation marker HLADR; increased density of endometrial macrophages; and decreased density of endometrial regulatory T cells. Unlike previous reports with samples from the vagina, we did not observe increased expression of the HIV co-receptor CCR5 on CD4+ T cells in the endocervix or endometrium. Our results indicate important differences in anatomic compartments regarding mechanisms by which depot-medroxyprogesterone acetate could be associated with increased risk of HIV acquisition, including increased recruitment of macrophages to the endometrium, decreased levels of pro-inflammatory cytokines in the endocervix possibly leading to enhanced susceptibility to viral infection, and activation of endometrial T cells.

Indexed as

AdultCD4-Positive T-LymphocytesCellular MicroenvironmentCervix UteriChemokine CCL2Contraceptive AgentsDelayed-Action PreparationsDisease SusceptibilityEndometriumFemaleHIV InfectionsHumansInterferon-alphaInterleukin-1betaInterleukin-6Medroxyprogesterone AcetateCCL2 protein, humanCCR5 protein, humanChemokine CCL2Contraceptive AgentsDelayed-Action PreparationsInterferon-alphaInterleukin-1betaInterleukin-6Medroxyprogesterone AcetateReceptors, CCR5

Identifiers

PMID28051087
PMCPMC5496803
OpenAlexW2570519144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.